Kura Oncology Announces Board and Executive Changes
Ticker: KURA · Form: 8-K · Filed: Jan 6, 2025 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Jan 6, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
TL;DR
Kura Oncology reshuffled its board and exec pay effective Jan 1, 2025.
AI Summary
Kura Oncology, Inc. announced on January 1, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company elected new directors and made adjustments to compensatory arrangements for certain officers. These changes are effective as of January 1, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine corporate governance changes and executive compensation adjustments, which are common and typically do not represent significant new risks.
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- January 1, 2025 (date) — Effective date of changes
FAQ
Who were the specific directors elected or departed?
The filing does not specify the names of the directors elected or departed, only that there were changes in the board of directors.
What were the specific changes to compensatory arrangements?
The filing indicates adjustments to compensatory arrangements for certain officers but does not detail the specifics of these changes.
What is the effective date of these changes?
The effective date for the reported events, including the departure of directors, election of directors, and changes in compensatory arrangements, is January 1, 2025.
Are there any new executive officers appointed?
The filing mentions the appointment of certain officers as part of the Item 5.02 disclosure, but does not name them or specify if they are new.
What is the primary business of Kura Oncology, Inc.?
Kura Oncology, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2025-01-06 16:35:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
Filing Documents
- d912671d8k.htm (8-K) — 24KB
- 0001193125-25-002189.txt ( ) — 143KB
- kura-20250101.xsd (EX-101.SCH) — 3KB
- kura-20250101_lab.xml (EX-101.LAB) — 18KB
- kura-20250101_pre.xml (EX-101.PRE) — 11KB
- d912671d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kura Oncology, Inc. Date: January 6, 2025 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer